Cargando…
Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside
Acute hypoxia and chronic hypoxia induce pulmonary vasoconstriction. While hypoxic pulmonary vasoconstriction is a physiological response if parts of the lung are affected, global exposure to hypoxic conditions may lead to clinical conditions like high-altitude pulmonary hypertension. Nitric oxide i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158260/ https://www.ncbi.nlm.nih.gov/pubmed/32313644 http://dx.doi.org/10.1177/2045894020918846 |
_version_ | 1783522502037733376 |
---|---|
author | Hannemann, Juliane Zummack, Julia Hillig, Jonas Böger, Rainer |
author_facet | Hannemann, Juliane Zummack, Julia Hillig, Jonas Böger, Rainer |
author_sort | Hannemann, Juliane |
collection | PubMed |
description | Acute hypoxia and chronic hypoxia induce pulmonary vasoconstriction. While hypoxic pulmonary vasoconstriction is a physiological response if parts of the lung are affected, global exposure to hypoxic conditions may lead to clinical conditions like high-altitude pulmonary hypertension. Nitric oxide is the major vasodilator released from the vascular endothelium. Nitric oxide-dependent vasodilation is impaired in hypoxic conditions. Inhibition of nitric oxide synthesis is the most rapid and easily reversible molecular mechanism to regulate nitric oxide-dependent vascular function in response to physiological and pathophysiological stimuli. Asymmetric dimethylarginine is an endogenous, competitive inhibitor of nitric oxide synthase and a risk marker for major cardiovascular events and mortality. Elevated asymmetric dimethylarginine has been observed in animal models of hypoxia as well as in human cohorts under chronic and chronic intermittent hypoxia at high altitude. In lowlanders, asymmetric dimethylarginine is high in patients with pulmonary hypertension. We have recently shown that high asymmetric dimethylarginine at sea level is a predictor for high-altitude pulmonary hypertension. Asymmetric dimethylarginine is a highly regulated molecule, both by its biosynthesis and metabolism. Methylation of L-arginine by protein arginine methyltransferases was shown to be increased in hypoxia. Furthermore, the metabolism of asymmetric dimethylarginine by dimethylarginine dimethylaminohydrolases (DDAH1 and DDAH2) is decreased in animal models of hypoxia. Whether these changes are caused by transcriptional or posttranslational modifications remains to be elucidated. Current data suggest a major role of asymmetric dimethylarginine in regulating pulmonary arterial nitric oxide production in hypoxia. Further studies are needed to decipher the molecular mechanisms regulating asymmetric dimethylarginine in hypoxia and to understand their clinical significance. |
format | Online Article Text |
id | pubmed-7158260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-71582602020-04-20 Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside Hannemann, Juliane Zummack, Julia Hillig, Jonas Böger, Rainer Pulm Circ Special Issue for the 1st international DECIPHER Symposium on Hypoxia and the Lung Acute hypoxia and chronic hypoxia induce pulmonary vasoconstriction. While hypoxic pulmonary vasoconstriction is a physiological response if parts of the lung are affected, global exposure to hypoxic conditions may lead to clinical conditions like high-altitude pulmonary hypertension. Nitric oxide is the major vasodilator released from the vascular endothelium. Nitric oxide-dependent vasodilation is impaired in hypoxic conditions. Inhibition of nitric oxide synthesis is the most rapid and easily reversible molecular mechanism to regulate nitric oxide-dependent vascular function in response to physiological and pathophysiological stimuli. Asymmetric dimethylarginine is an endogenous, competitive inhibitor of nitric oxide synthase and a risk marker for major cardiovascular events and mortality. Elevated asymmetric dimethylarginine has been observed in animal models of hypoxia as well as in human cohorts under chronic and chronic intermittent hypoxia at high altitude. In lowlanders, asymmetric dimethylarginine is high in patients with pulmonary hypertension. We have recently shown that high asymmetric dimethylarginine at sea level is a predictor for high-altitude pulmonary hypertension. Asymmetric dimethylarginine is a highly regulated molecule, both by its biosynthesis and metabolism. Methylation of L-arginine by protein arginine methyltransferases was shown to be increased in hypoxia. Furthermore, the metabolism of asymmetric dimethylarginine by dimethylarginine dimethylaminohydrolases (DDAH1 and DDAH2) is decreased in animal models of hypoxia. Whether these changes are caused by transcriptional or posttranslational modifications remains to be elucidated. Current data suggest a major role of asymmetric dimethylarginine in regulating pulmonary arterial nitric oxide production in hypoxia. Further studies are needed to decipher the molecular mechanisms regulating asymmetric dimethylarginine in hypoxia and to understand their clinical significance. SAGE Publications 2020-04-14 /pmc/articles/PMC7158260/ /pubmed/32313644 http://dx.doi.org/10.1177/2045894020918846 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Special Issue for the 1st international DECIPHER Symposium on Hypoxia and the Lung Hannemann, Juliane Zummack, Julia Hillig, Jonas Böger, Rainer Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside |
title | Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside |
title_full | Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside |
title_fullStr | Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside |
title_full_unstemmed | Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside |
title_short | Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside |
title_sort | metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside |
topic | Special Issue for the 1st international DECIPHER Symposium on Hypoxia and the Lung |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158260/ https://www.ncbi.nlm.nih.gov/pubmed/32313644 http://dx.doi.org/10.1177/2045894020918846 |
work_keys_str_mv | AT hannemannjuliane metabolismofasymmetricdimethylarginineinhypoxiafrombenchtobedside AT zummackjulia metabolismofasymmetricdimethylarginineinhypoxiafrombenchtobedside AT hilligjonas metabolismofasymmetricdimethylarginineinhypoxiafrombenchtobedside AT bogerrainer metabolismofasymmetricdimethylarginineinhypoxiafrombenchtobedside |